Patents Examined by Theodore R West
  • Patent number: 10369170
    Abstract: Provided herein are methods of treating basal cell carcinoma or glioblastoma by administering coal tar or a coal tar product to a patient with basal cell carcinoma or glioblastoma. The coal tar or coal tar product may be administered as a standalone therapy or in combination with other treatments for basal cell carcinoma or glioblastoma.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: August 6, 2019
    Inventor: Carol J. Buck
  • Patent number: 10369118
    Abstract: A method for reducing scarring comprises applying into a wound a composition comprising resveratrol. The wound was formed at most one day before the applying, and no part of the skin surface of the wound is more than 3 cm from uninjured skin.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 6, 2019
    Assignee: Cole Research & Design, LLC
    Inventor: Jeptha N. Cole
  • Patent number: 10369226
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: August 6, 2019
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Patent number: 10350153
    Abstract: Topical compositions comprising a retinoid, a low irritation polymeric cleansing agent and a cosmetically-acceptable topical carrier are provided. Such compositions provide improved retinoid activity for treating for example signs of skin aging, acne, or rosacea.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: July 16, 2019
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Michael Chang, Michael James Fevola, Simarna Kaur, Michael D. Southall, Ali Fassih
  • Patent number: 10335367
    Abstract: Selected anticholinergic zwittehons are administered to slow the progression of myopia in children and to treat myopia generally.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 2, 2019
    Assignee: BODOR LABORATORIES, INC.
    Inventor: Nicholas S. Bodor
  • Patent number: 10328073
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: June 25, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Patent number: 10328058
    Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 25, 2019
    Assignees: Mayo Foundation for Medical Education and Research, Unity Biotechnology, Inc., Buck Institute for Research on Aging
    Inventors: Darren J. Baker, Marco Demaria, Albert Davalos, Bennett G. Childs, Jan M. A. van Deursen, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Remi-Martin Laberge, Judith Campisi
  • Patent number: 10322118
    Abstract: The present invention provides a screening assay for identifying inhibitors of Pseudomonas aeruginosa CFTR Inhibitory Factor as well as compositions and methods for ameliorating or treating a respiratory disease such as cystic fibrosis or secondary infection thereof.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: June 18, 2019
    Assignees: TRUSTEES OF DARTMOUTH COLLEGE, THE REGENTS OF TE UNIVERSITY OF CALIFORNIA
    Inventors: Dean R. Madden, Christopher D. Bahl, Bruce D. Hammock, Christophe Morisseau
  • Patent number: 10322183
    Abstract: Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: June 18, 2019
    Assignee: PHARMA MAR, S.A., SOCIEDAD UNIPERSONAL
    Inventors: Jacob Hendrik Beijnen, Bastiaan Nuijen, Pilar Calvo Salve, Maria Tobio Barreira
  • Patent number: 10307414
    Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: June 4, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
  • Patent number: 10301298
    Abstract: Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: May 28, 2019
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Nicos A. Petasis, Kathleen E. Rodgers, Stan G. Louie, Gere S. DiZerega, Kevin J. Gaffney
  • Patent number: 10300299
    Abstract: The present invention relates to methods for treating cell proliferation disorders comprising: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated; (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder; and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell prolifer
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: May 28, 2019
    Assignees: Immunolight, LLC, Duke University
    Inventors: Frederic A. Bourke, Jr., Tuan Vo-Dinh
  • Patent number: 10292988
    Abstract: This invention discloses uses for estrone in preparing anti-ovarian cancer and/or breast cancer products. This invention provides uses for estrone in the preparation of products to treat ovarian cancer and/or breast cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug estrone, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that estrone has a new use as an anti-ovarian cancer and/or anti-breast cancer medication, thus achieving a new purpose for an old drug.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: May 21, 2019
    Assignee: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Yongyong Shi, Zhijian Song
  • Patent number: 10292953
    Abstract: The present invention relates to a pharmaceutical composition of ibuprofen and tramadol for ophthalmic use. Said composition is effective and safe for the treatment of ocular inflammation and/or pain associated to different diseases or pathological states which affect the eye area In particular, the ophthalmic composition of the invention is indicated, for example, for the treatment of pain and/or inflammation after eye surgery.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: May 21, 2019
    Inventors: Fernando Martinez-Alzamora, Jose Miguel Rizo Martinez, Antonia Gomez Calvo, Nuria Sanz Menendez, Angel Munoz Ruiz
  • Patent number: 10292389
    Abstract: The disclosure provides a pediculicidal composition comprising a metal chelating agent; a carrier vehicle comprising water and an activating solvent system comprising an alcohol and a hydrocarbon. The carrier vehicle may be in the form of a solution, a cream, an ointment, a foam, a spray, an emulsion or a gel. The disclosure also provides method for use of a pediculicidal composition to treat human head lice and their eggs and methods for controlling head lice infestation.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 21, 2019
    Assignee: DR. REDDY'S LABORATORIES, S.A.
    Inventors: Ronald Harding, Lewis David Schulz, Vernon Morrison Bowles
  • Patent number: 10280169
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: May 7, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Gnanasambandam Kumaravel, Hua Miao, Andrea Bertolotti-Ciarlet, Kevin Otipoby
  • Patent number: 10258618
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: April 16, 2019
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH AGING, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M. A. van Deursen
  • Patent number: 10251836
    Abstract: A method and intravaginal drug delivery device for reducing size of endometrial implants in a female in need thereof are provided. The method includes administering intravaginally to the female a therapeutically effective amount of an active agent, wherein the agent is delivered on a delivery device directly to the endometrial implants, wherein said amount is able to significantly reduce the size of endometrial implants, wherein the active agent is any one of selective progesterone receptor modulator (SPRM), an anti-progestin agent, and an anti-progestational agent.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: April 9, 2019
    Assignee: Arstat, Inc.
    Inventor: Arkady Rubin
  • Patent number: 10246461
    Abstract: The invention relates generally to pharmaceutical tablet compositions comprising fumaric acid and the compound (S)-2-(3?-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4?-bipyridin]-2?-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one free base that is an inhibitor of Bruton's tyrosine kinase. The invention further relates to amorphous solid dispersions comprising at least one polymer and the Bruton's kinase inhibitor free base compound. The invention further relates to crystalline mesylate salts, crystalline chloride salts and crystalline sulfate salts of the Bruton's kinase inhibitor free base compound. In some aspects, the crystalline salts are single polymorphs.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Chen Mao, Dawen Kou, Po-Chang Chiang
  • Patent number: 10238617
    Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: March 26, 2019
    Assignee: AXCELLA HEALTH INC.
    Inventors: Michael Hamill, Raffi Afeyan, Chung-Wei Lee, Harry Luithardt, David Berry